AVTX · Avalo Therapeutics, Inc.
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Dec 29, 2023; bars on opposite sides are not compared.
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AVTX
this stock
Avalo Therapeutics, Inc.
|
$1.03B | +5.9% | +2312.3% | — | 24.4% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$138.42B | +20.5% | +46.2% | 31.8 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$85.22B | +7.2% | +20.8% | 20.5 | 2.3% |
|
ARGX
Argenx SE
|
$64.25B | +22.9% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$60.55B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Dec 29, 2023; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AVTX | -1.8% | +5.0% | +20.0% | -0.6% | +5.9% |
| SPY | +0.1% | -0.4% | +15.1% | +0.4% | +12.9% |
| vs SPY | -2.0% | +5.4% | +4.9% | -1.0% | -7.1% |